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Receptor for advanced glycation end products (RAGE) is involved in the pathogenesis
of Alzheimer’s disease. We have previously revealed that RAGE fragment sequence
(60–76) and its shortened analogs sequence (60–70) and (60–65) under intranasal
insertion were able to restore memory and improve morphological and biochemical
state of neurons in the brain of bulbectomized mice developing major AD features. In
the current study, we have investigated the ability of RAGE peptide (60–76) and five
shortened analogs to bind beta-amyloid (Aβ) 1–40 in an fluorescent titration test and
show that all the RAGE fragments apart from one [sequence (65–76)] were able to bind
Aβ in vitro. Moreover, we show that all RAGE fragments apart from the shortest one (60–
62), were able to protect neuronal primary cultures from amyloid toxicity, by preventing
the caspase 3 activation induced by Aβ 1–42. We have compared the data obtained in
the present research with the previously published data in the animal model of AD, and
offer a probable mechanism of neuroprotection of the RAGE peptide.
Keywords: beta-amyloid, synthetic peptides, receptor for advanced glycation end products, Alzheimer’s disease,
primary cell culture
INTRODUCTION
The receptor for advanced glycation end products (RAGE) is a multiligand polyfunctional receptor,
which takes part in the pathology of many diseases (Deane, 2012). In particular, RAGE is involved
in the pathology of Alzheimer’s disease (AD) by activating neuroinflammation (Ramasamy et al.,
2009), inducing neuronal dysfunction (Perrone et al., 2012), and mediating the transport of
pathological beta-amyloid (Aβ) from the blood into the brain (Yan et al., 2010). It has been shown
that in human AD brains, the level of RAGE expression is increased in neuronal and microglial
cells and its expression is correlated to the severity of the disease (Yan et al., 1996; Lue et al., 2001;
Leclerc et al., 2010). Transgenic mice overexpressing RAGE in neurons or microglia demonstrated
enhanced Aβ production, enhanced neurotoxicity, reduced cognition and enhanced inflammation
(Walker et al., 2015).
Previously, we had shown that synthetic RAGE fragment sequence (60–76) protects spatial
memory of mice with an experimentally induced form of AD (olfactory bulbectomized mice),
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improves the morphological and functional state of the neurons
and lowers the level of brain Aβ in experimental animals (Volpina
et al., 2015, 2018). In our research, we revealed that shortened
RAGE fragments have also a protective activity in the animal
model: fragment sequence (60–70) has almost the same activity
as (60–76), while fragment (60–65) was less effective (Volpina
et al., 2018). These results obtained in the animal model led us
to investigate in more detail the mechanism of neuroprotection
of the RAGE peptide (60–76).
We demonstrated that peptide (60–76) binds amyloid plaques
in Tg-5xFAD mice brain slices and Aβ 1–40 trimer in low SDS
electrophoresis. We proposed that one of the possible protective
pathways of the peptide (60–76) might be the result of its
binding to Aβ. To identify the conditions under which the RAGE
fragment develops its protective activity, we have investigated
whether peptide (60–76) and its shortened analogs bind Aβ
in vitro.
One of the key stages in AD development is the death of
neurons and astrocytes in the hippocampus and cortex (Sadigh-
Eteghad et al., 2015; Hardy and Selkoe, 2016). In order to reveal
the protective activity of the chosen RAGE fragments in vitro, in
the current research we have also investigated whether the RAGE
peptides were able to reduce the amyloid-induced toxicity in Aβ
1–42-treated primary cultures of neurons and astrocytes derived
from hippocampal and cortical areas of rats’ brains.
The data obtained in the present study have been compared
with our previous results showing the protective activity of
the RAGE fragments in the animal model of AD (olfactory
bulbectomized mice), and we have identified the most active
RAGE fragment. Here, we also discuss the possible mechanism
of neuroprotection of the active peptide.
MATERIALS AND METHODS
Peptide Synthesis
RAGE fragments presented in Table 1 were derived from the
sequences of human RAGE (Q15109 UniProtKB/SwissProt).
Human Aβ1–40 was derived from sequences of human amyloid
precursor protein (P05067.3, UniProtKB/Swiss-Prot). RAGE
peptides and Aβ1–40 were synthesized on the Wang resin using
the Fmoc/But-scheme as described previously in Volpina et al.
(2018). The peptides were purified by HPLC on C18 column
(Phenomenex Jupiter 10 µ C18 300A 250 × 10 mm) in the
acetonitrile gradient from 10 to 70% in 0.1% TFA (registration
at 226 nm). Synthetic peptides were characterized by analytical
reversed-phase HPLC on C18 column (Phenomenex Jupiter
5 µ C18 300A 250 × 4.6 mm) and MALDI-MS on VISION
2000 (Bioanalysis, United Kingdom). Purity of the peptides was
estimated as> 95%.
Fluorescent Titration of RAGE
Fragments by Aβ 1–40
The fluorescence titrations of synthetic peptides were performed
using Fluoromax 3 fluorescence spectrophotometer (Horiba
Jobin Yvon, Germany). Titrations were conducted in a quartz
cuvette with 2 ml of titration buffer (25 mM Tris-HCl,
TABLE 1 | Amino acid sequences of the chosen RAGE fragments.







100 mM NaCl, 5 mM EDTA, pH 7.5). The concentration
of peptide (60–76) which has two tryptophan residues was
0.5 µM. Whereas peptides (60–70), (60–62), (60–65), (62–73),
and (65–76) have only one Trp residue, their concentration
was 2 µM to enhance the signal. Lyophilized synthetic Aβ
1–40 was dissolved in mili-Q water at a concentration of
1 mM. In experiments with (60–76), beta-amyloid was diluted
in titration buffer to 100µM and added with the step of
100 nM to form concentrations from 100to 1500 nM in the
cuvette. During the titrations of (60–70), (60–62), (60–65),
(62–73), and (65–76) we added increasing concentrations of
Aβ 1–40 at 200, 400, 800, 1200, 1600, 2000, 2400, 2800,
3200, 3600, and 4000 nM, which was previously diluted 2.5
times.
The fluorescence spectrum was measured after each addition
of beta-amyloid. The excitation wavelength was λ = 285 nm.
Emission was detected in the range of 250–450 nm. The
maximum of fluorescence intensity was found at 355 nm. In
Statistica 10 (StatSoft United States) the set of intensities were
distributed on a plot with coordinates 1/[S] versus 1/1F and were









where [S] – concentration of Aβ 1–40 in cuvette; 1F is the
difference of intensity between experiment in absence of Aβ 1–40
and experiment with beta-amyloid at the certain concentration
and 1Fmax is the maximal fluorescence change (Huang et al.,
2016). The linear distribution was plotted by least square method
and characterized by the coefficient of determination R2 and
standard error of estimation (SEE). These values are presented
at Table 2. The distribution was acceptable when R2 ≥ 0.8.
TABLE 2 | Characteristics of linear distributions obtained during the fluorescent








R2 for all peptides, except P5, are more than R2 = 0.8.
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FIGURE 1 | Identification of the binding affinities of peptides P1 (A,B) and P2 (C,D) with Aβ 1–40 by fluorescence spectroscopy. (A) Emission spectra of 0.5 µM P1
peptide fluorescence titrations exhibit decreasing fluorescence intensities with increasing concentration of Aβ 1–40 in range 0–1500 nM. (B) Curve with P1
fluorescence intensity changes versus Aβ 1–40 concentrations measured at a wavelength of 355 nm. (C) Emission spectra of 2 µM P2 peptide fluorescence
titrations exhibit decreasing fluorescence intensities with increasing concentration of Aβ 1–40 in range 0–4000 nM. (D) Curve with P2 fluorescence intensity changes
versus Aβ 1–40 concentrations measured at a wavelength of 355 nm. Linear equations were utilized for the dissociation constants (Kd) calculations (B,D).
The dissociation constant Kd was found by multiplication of
the calculated slope factor and 1Fmax. For each peptide the
dissociation constant was measured three times independently.
Dissociation constants were expressed as mean ± SEM. P-values
were measured by Mann-Whitney test to estimate the differences
between each of obtained dissociation constants.
Cell Culture
Mixed cultures of hippocampal and cortical neurons and glial
cells were prepared as described previously (Vaarmann et al.,
2010) with modifications, from Sprague-Dawley rat pups 2–
4 days post-partum (UCL breeding colony). Experimental
procedures were performed in full compliance with the
United Kingdom Animal (Scientific Procedures) Act of 1986 and
with approval of the University College London Animal Ethics
Committee. Hippocampi and cortex were removed into ice-cold
PBS (Ca2+, Mg2+-free, Invitrogen, Paisley, United Kingdom).
The tissue was minced and trypsinised (0.25% for 15 min at
37◦C), triturated and plated on Poly-D-lysine-coated coverslips
and cultured in Neurobasal A medium (Invitrogen, Paisley,
United Kingdom) supplemented with B-27 (Invitrogen, Paisley,
United Kingdom) and 2 mM L-glutamine. Cultures were
maintained at 37◦C in a humidified atmosphere of 5% CO2 and
95% air, fed twice a week and maintained for a minimum of 12
days before experimental use to ensure expression of glutamate
and other receptors. Neurons were easily distinguishable from
glia: they appeared phase bright, had smooth rounded somata
and distinct processes, and lay just above the focal plane of the
glial layer. Cells were used at 12–15 days in vivo (DIV) unless
otherwise stated.
Caspase 3 Activity Assay
For the measurement of caspase 3 activation, cells were loaded
for 15 min at room temperature with 10 µM NucView 488
caspase 3 substrate (Biotium, United States) in HBSS. NucView
488 is a novel class of enzyme substrates for real-time detection
of caspase-3 activity in live cells. The substrate can rapidly
cross cell membrane to enter the cell cytoplasm, where it is
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FIGURE 2 | Identification of the binding affinities of peptides P3 (A,B) and P4 (C,D) with Aβ 1–40 by fluorescence spectroscopy. (A) Emission spectra of 2 µM P3
peptide fluorescence titrations exhibit decreasing fluorescence intensities with increasing concentration of Aβ 1–40 in range 0–4000 nM. (B) Curve with P3
fluorescence intensity changes versus Aβ 1–40 concentrations by measurement at a wavelength of 355 nm. (C) Emission spectra of 2 µM P4 peptide fluorescence
titrations exhibit increasing fluorescence intensities with increasing concentration of Aβ 1–40 in range 0–4000 nM. (D) Curve with P4 fluorescence intensity changes
versus Aβ 1–40 concentrations measured at a wavelength of 355 nm. Linear equations were utilized for the dissociation constants (Kd) calculations (B,D).
cleaved by caspase-3 to release the high-affinity DNA dye.
The released DNA dye migrates to the cell nucleus to stain
the nucleus brightly green. Cells were pre-incubated for 3 h
with 10 µM of each peptide. Then, cells were treated for
1 h with 5 µM Aβ 1–42 (Bachem, Cambridge Bioscience).
Beta-amyloid 1–42 was prepared as described previously in
Narayan et al. (2014). Confocal images were obtained using
Zeiss (Oberkochen, Germany) 710 confocal laser scanning
microscope and a 40× oil immersion objective. The 488 nm
argon laser was used to excite NucView 488 fluorescence,
which was measured using a bandpass filter from 510 and
560 nm. All of the data shown were obtained from at least 5
coverslips and 2–3 different cell preparations. N corresponds to
the number of fields taken for cell calculation from coverslips.
The number of cells with activated caspase 3 and the number
of all visible cells was quantified manually in each field and
the percentage of dead cells was calculated by dividing the
number of caspase 3-positive cells by the number of all cells
counted in one field. The differences between the groups were
evaluated using the two-sample t-test. All data were expressed




In this study we used a panel of synthetic peptides listed
in Table 1 including full-size peptide (60–76) and truncated
overlapping fragments. Peptides (60–70), (60–65), and (60–62)
are truncated at the C-terminus fragments of the peptide (60–
76). The peptide (62–73) was shortened both to the N-terminal
and to the C-terminal sequence. The peptide (65–76) is devoid of
the N-terminal sequence.
Fluorescent Titration of RAGE
Fragments by Aβ 1–40
We proposed previously that one of the protection pathways
influenced by the peptide (60–76) is the interaction of P1 with
Aβ. Fluorescent titrations of P1 peptide and its fragments by
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FIGURE 3 | Identification of the binding affinities of peptides P5 (A,B) and P6 (C,D) with Aβ 1–40 by using fluorescence spectroscopy. (A) Emission spectra of 2 µM
P5 peptide fluorescence titrations exhibit the absence of consecutive changes in fluorescence intensities with increasing concentration of Aβ 1–40 in range
0–4000 nM. (B) Curve with P5 fluorescence intensity changes versus Aβ 1–40 concentrations by measurement at a wavelength of 355 nm. The non-linear fitting of
P5 titration data demonstrated the absence of binding with Aβ 1–40 and did not allow finding a dissociation constant. (C) Emission spectra of 2 µM P6 peptide
fluorescence titrations exhibit decreasing fluorescence intensities with increasing concentration of Aβ 1–40 in range 0–4000 nM. (D) Curve with P6 fluorescence
intensity changes versus Aβ 1–40 concentrations measured at a wavelength of 355 nm. Linear equation was utilized for the dissociation constant (Kd)
calculations (D).
Aβ 1–40 were conducted to study their ability to bind beta-
amyloid in vitro. We preferred this method because it did not
require using any additional fluorescent label, but only the
peptide tryptophan residues as the source of fluorescence, which
preserves the native peptide conformation and solubility. It is
known that tryptophan fluorescence is very sensitive to the
binding of the target peptides with ligands (Huang et al., 2016).
Aβ 1–40 was utilized for an accurate control of the concentrations
in the cuvette due to its higher solubility in comparison with the
Aβ 1–42 isoform (Olivero et al., 2014). During the titration of
P1–P6 fragments, the intensity of emission changes linearly for
five fragments – for P1, P2, P3, P4, and P6 (Figures 1–3).
The data of P5 titration was irregular and did not give a strong
linear distribution (R2 < 0.8). It was shown that peptides P1–
P4 and P6, but not the fragment truncated at the N-terminus
(P5) (Figure 3), specifically bound to Aβ 1–40. The dissociation
constants for complexes of these peptides with Aβ 1–40 are
presented in the Table 3. The dissociation constant (Kd) for
TABLE 3 | Interactions between RAGE fragments and Aβ 1–40.
Peptide Kd, µM∗ p-value∗∗
P1 1.39 ± 0.36
P2 4.06 ± 0.76 0.045
P3 0.84 ± 0.17 0.716
P4 2.81 ± 0.53 0.112
P5 No binding –
P6 1.53 ± 0.14 0.377
∗The dissociation constants Kd are presented as mean ± SEM of three
independent experiments. ∗∗p-values were calculated to estimate the statistical
significance between the dissociation constants for P2–P6 fragments versus Kd for
P1 peptide.
full-size P1 peptide was established at the level of ∼1.4 µM. The
values of Kd for P3, P4, and P6 fragments were found equal with
the Kd for P1 (p > 0.05). The only shortened peptide with a
significantly different dissociation constant to P1 (p = 0.045) was
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P2 with a Kd of around 4.1 µM. To sum up, the fluorescence
titrations demonstrated that the interactions between Aβ 1–40
and all of the peptides, except P5, are at the micromolar level,
provided that the amyloid-peptide complexes are very stable in
the conditions of this experiment (Huang et al., 2016).
Caspase-3 Activation Test
To investigate the protective activity of the RAGE peptides, we
treated primary cultures of neurons and astrocytes derived from
hippocampal and cortical areas of rats’ brains, with Aβ 1–42.
Aβ can trigger the cell death cascade by activation of caspase
3 (Harada and Sugimoto, 1999; Kamynina et al., 2013). For the
evaluation of the protective activity of the RAGE fragments, the
culture was preliminary incubated for 3 h with each of the six
peptides. After that, the culture was incubated for 1 h with Aβ 1–
42. The visualization of the caspase 3 activation in real time was
conducted using NucView 488 caspase 3 substrate.
It was shown that application of Aβ 1–42 induced a rapid
activation of caspase 3 in neurons and astrocytes derived from
hippocampal and cortical areas of rats’ brains (percentage of cells
with activated caspase 3 = 35.345 ± 3.41; N = 20, Table 4 and
Figure 5) in comparison with the control non-treated culture
(percentage of dead cells = 11.075 ± 1.54; N = 20). It should
be noted that pre-incubation of the cultures with five RAGE
fragments (P1, P2, P4, P5, and P6) reduced the Aβ 1–42 induced
rate of appearance of caspase 3 activation and the percentage of
dead cells with green nuclei with different significance (N = 6–
28) (Table 4 and Figures 4, 5). The most protective activity was
achieved with fragments P1, P2, and P6, which were able to
significantly reduce Aβ activated caspase 3 (p< 0.001, percentage
of dead cells = 18.13 ± 2.05; N = 28, 13.07 ± 2.71; N = 12 and
8.53 ± 2.72; N = 6, respectively). The activity of Aβ-activated
caspase 3 was also significantly (p < 0.01) reduced after pre-
incubation with P4 (percentage of dead cells = 15.5± 3.27; N = 6)
TABLE 4 | Percentage of cells with activated caspase 3 following application of Aβ
1–42 and one of the RAGE fragments to primary cultures of neurons and
astrocytes derived from hippocampal and cortical areas of rats’ brains.
N Mean, % SEM p-valuea
Not treated 20 11.075 1.53647 <0.0001 ∗∗∗
Aß 1–42 20 35.345 3.41302
Aß + P1 28 18.12857 2.04813 <0.0001 ∗∗∗
Aß + P2 12 13.06667 2.70771 <0.0001 ∗∗∗
Aß + P3 18 27.36667 2.79309 0.0827 –
Aß + P4 6 15.53333 3.26748 0.00583 ∗∗
Aß + P5 6 14.25 3.22229 0.00361 ∗∗
Aß + P6 6 8.53333 2.72013 <0.0001 ∗∗∗
∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001.
N corresponds to the number of fields. The number of cells with activated caspase
3 and the number of all visible cells was quantified manually in each field and the
percentage of dead cells was calculated by dividing the number of dead cells by
the number of all cells counted in one field.
ap-values were calculated to estimate statistical significance between the group of
cells after application of Aβ 1–42 versus group of not treated culture or the culture
treated with Aβ 1–42 and one of the RAGE fragments (P1–P6).
and P5 (percentage of dead cells = 14.25 ± 3.22; N = 6). Only
peptide P3 did not decrease the rate of Aβ-induced caspase 3
activation (number of cells = 27.37± 2.79; N = 18, Figure 5).
DISCUSSION
Previously, we have shown that intranasal administration of
RAGE fragments resulted in the improvement of both spatial
memory and morpho-functional characteristics in the brain of
mice with experimentally induced AD (Volpina et al., 2018).
Peptide P1 (60–76) showed the most successful activity in both
parameters. Administration of the shorter fragment P2 (60–
70) also prevented memory loss in the experimental animals.
FIGURE 4 | Percentage of cells with activated caspase 3 following application of Aβ 1–42 and one of the RAGE fragments to primary cultures of neurons and
astrocytes derived from hippocampal and cortical areas of rats’ brains (N = 6–28 fields). Percentage of dead cells was calculated by dividing the number of cells with
activated caspase 3 (cells with green nuclei) by the number of all cells counted in one field. The data are presented as mean ± SD. ∗p < 0.05; ∗∗p < 0.01;
∗∗∗p < 0.001; Aβ 1–42 versus not treated culture; or Aβ 1–42 versus RAGE fragments (P1–P6).
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FIGURE 5 | Photomicrographs of cells with activated caspase 3 after treatment with beta-amyloid 1–42 and peptides P2 or P3. Green nuclei appear in the cells with
activated caspase 3.
The short peptide P4 (60–65) had protective activity on mouse
memory, but not significantly different from the control group
of non-treated mice. Experiments in the animal model also
showed the binding of peptide (60–76) with amyloid plaques.
This suggested that active fragments may exert their protective
action through their binding with Aβ (Volpina et al., 2018).
To test this hypothesis we investigated the binding of the
synthetic fragments with Aβ 1–40 by fluorescent titration. Aβ
1–40 is known to have more solubility (Olivero et al., 2014;
Iljina et al., 2016), than Aβ 1–42, which makes this isoform
more preferable for in vitro binding experiments. As a result
of the fluorescent titration, we have depicted that five of
the fragments (P1, P2, P3, P4, and P6) were able to bind
Aβ 1–40 in vitro with micromolar level of Kd. Only one
fragment, P5, did not form a complex with Aβ under these
conditions.
To investigate the effect of the RAGE fragments on Aβ toxicity,
we evaluated the rate of caspase 3 activation in primary neuronal
cultures, after the application of Aβ and the RAGE fragments.
Since Aβ 1–42 is known to have more toxic effects in comparison
with Aβ 1–40 (Favaloro et al., 2012; Pauwels et al., 2012; Cies´lik
et al., 2015), for the caspase 3 assays we used Aβ peptide 1–42.
In the present research, we show that treatment of the culture
with Aβ 1–42 results in a significant enhancement of caspase 3
activation and hence, cell death. Pre-incubation of the culture
with P1 (60–76) and its shortened analogs – P2 (60–70), P4 (60–
65), P5 (65–76) and P6 (62–73), leads to significant protection
of the cells from Aβ-induced death. It should be noted that P1
TABLE 5 | Effects of the RAGE peptides observed in animal tests, caspase 3
activity, study and fluorescent titration by Aβ 1–40.
Peptide Number Memory protection





P1 60–76 + + +
P2 60–70 + + +
P3 60–62 – – +
P4 60–65 ± + +
P5 65–76 – + –
P6 62–73 – + +
“+,” indicates the presence of positive effect; “−,” its absence.
(60–76), P2 (60–70), and P6 (62–73) fragments demonstrated the
most protective activity on the rate of caspase 3 induction.
We have also compared the data obtained in the present study
with the previously obtained data demonstrating the protective
activity of the peptides on the memory loss of experimental
animals (Table 5). The most active fragments in the animal
model, peptides P1 (60–76) and P2 (60–70), were able not only
to significantly prevent the activation of cell death in response to
addition of Aβ, but also bind Aβ in vitro.
The short peptide P4 (60–65), showed protective activity in the
animal test, but not significantly different from the activity of the
peptide P2 (60–70), and the statistical processing of the obtained
data did not allow to obtain reliable differences from the group of
not treated bulbectomized animals. For this reason, the data for
this peptide in Table 5 are shown as ±. As a result of the present
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research it was revealed that peptide P4 was able to protect cells
from Aβ induced cell death and bind Aβ.
Peptides P3, P5, and P6 did not prevent memory loss
occurring in the experimental mice as shown in our previous
study. However, these fragments act differently in the present
research. In particular, fragment P3 did not inhibit Aβ toxicity in
cells, but bound Aβ 1–40; fragment P5 did not bind Aβ 1–40, but
significantly decreased the number of cells with activated caspase
3 appearing in response to the application of Aβ 1–42. Peptide P6
induced both effects – it made a complex with Aβ and prevented
amyloid toxicity in the primary culture.
Thus, it seems that for the manifestation of a protective
activity in the animal tests, peptides should both inhibit caspase
3 activation induced by toxic Aβ and bind Aβ in vitro.
Considering the fact that some of the RAGE peptides which
protected cells from beta-amyloid toxicity did not bind beta-
amyloid in the fluorescent titration test (for instance, P5),
we propose that their protective activity is not connected
only with binding with amyloid but they are more likely
to mediate physiological functionality of the RAGE receptor.
The mechanism of memory protection appeared to be more
complicated than we had believed earlier. From one hand,
binding with Aβ and prevention of caspase activity offers only
one of the possible explanations why peptides preserve memory
state of olfactory bulbectomized animals. At the same time,
manifestation of both of these effects for a peptide is not sufficient
to stop memory loss progression observed in the experimental
animals. The mechanism of the protective activity of the peptides
is likely to be a result of additional pathways which are expected
to be revealed.
Despite numerous investigations, the role of RAGE molecule
in the pathology of AD is still not clear enough. The failure
of the third stage of clinical trials of azeliragon, which blocks
the binding of RAGE with its ligands (Godyn et al., 2016),
has demonstrated that participation of RAGE in AD is more
complicated than just binding with beta-amyloid. The data
shown here, regarding the activity of RAGE peptide (60–76) gives
new opportunities toward further investigation of the role of
this receptor in AD pathology and provides new pathways for a
potential drug treatment of this disease.
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